Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Papaioannou

Showing results (131-140 of 144) with videos related to

Pageof 15
Sort By:
Therapeutic Advances in Hematology|December 21, 2020
Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromesSotirios G Papageorgiou, Ioannis Kotsianidis, Anthi Bouchla, et al.
British Journal of Haematology|August 31, 2020
The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomesPanagiotis T Diamantopoulos, Argiris Symeonidis, Vasiliki Pappa, et al.
British Journal of Haematology|March 7, 2022
International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemiaSimone Oerlemans, Fabio Efficace, Jacobien M Kieffer, et al.
The Journal of Clinical Investigation|April 28, 2015
Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone diseaseAdel Ersek, Ke Xu, Aristotelis Antonopoulos, et al.
Annals of Hematology|July 3, 2026
Real-world treatment patterns and outcomes in chronic lymphocytic leukemia: a multicenter retrospective study in GreeceEpameinondas Koumpis, Eva Minga, Persefoni Talimtzi, et al.
Blood|March 12, 2025
Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1qRomanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Mairead Reidy, et al.
Annals of Hematology|February 1, 2021
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategiesTheodoros P Vassilakopoulos, Sotirios G Papageorgiou, Maria K Angelopoulou, et al.
The Oncologist|April 19, 2021
Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOPTheodoros P Vassilakopoulos, Michail Michail, Sotirios Papageorgiou, et al.
In Vivo (Athens, Greece)|April 28, 2022
Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell LymphomaStamatis J Karakatsanis, Maria Bouzani, Argyris Symeonidis, et al.
American Journal of Hematology|February 26, 2020
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study groupYair Herishanu, Adir Shaulov, Riva Fineman, et al.
Pageof 15

Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Therapeutic Advances in Hematology|December 21, 2020
Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromesSotirios G Papageorgiou, Ioannis Kotsianidis, Anthi Bouchla, et al.
British Journal of Haematology|August 31, 2020
The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomesPanagiotis T Diamantopoulos, Argiris Symeonidis, Vasiliki Pappa, et al.
British Journal of Haematology|March 7, 2022
International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemiaSimone Oerlemans, Fabio Efficace, Jacobien M Kieffer, et al.
The Journal of Clinical Investigation|April 28, 2015
Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone diseaseAdel Ersek, Ke Xu, Aristotelis Antonopoulos, et al.
Annals of Hematology|July 3, 2026
Real-world treatment patterns and outcomes in chronic lymphocytic leukemia: a multicenter retrospective study in GreeceEpameinondas Koumpis, Eva Minga, Persefoni Talimtzi, et al.
Blood|March 12, 2025
Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1qRomanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Mairead Reidy, et al.
Annals of Hematology|February 1, 2021
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategiesTheodoros P Vassilakopoulos, Sotirios G Papageorgiou, Maria K Angelopoulou, et al.
The Oncologist|April 19, 2021
Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOPTheodoros P Vassilakopoulos, Michail Michail, Sotirios Papageorgiou, et al.
In Vivo (Athens, Greece)|April 28, 2022
Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell LymphomaStamatis J Karakatsanis, Maria Bouzani, Argyris Symeonidis, et al.
American Journal of Hematology|February 26, 2020
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study groupYair Herishanu, Adir Shaulov, Riva Fineman, et al.
Pageof 15